成人癌症相关免疫抑制患者抗菌预防:ASCO与IDSA临床实践指南更新
ASCO与IDSA召集更新专家组,系统综述2011年5月至2016年11月相关研究,新增6项荟萃分析和6项原始研究,更新成人癌症相关免疫抑制患者抗菌预防推荐,涵盖细菌与真菌预防、抗病毒预防、肺孢子菌预防、乙型肝炎病毒再激活预防及疫苗接种等。
要点
- 预计出现深度、迁延性中性粒细胞减少(<100个中性粒细胞/µL持续>7天)或其他高危因素的患者推荐抗菌和抗真菌预防。
- 单纯疱疹病毒血清阳性患者接受异基因造血干细胞移植或白血病诱导治疗时,应接受核苷类似物抗病毒预防(如阿昔洛韦)。
- 化疗方案相关肺孢子菌肺炎风险>3.5%者推荐肺孢子菌预防(如泼尼松等效剂量≥20 mg/日持续≥1个月或基于嘌呤类似物使用)。
核心结论
- 更新版ASCO/IDSA指南推荐对感染高危的成人癌症相关免疫抑制患者进行抗菌、抗真菌及针对性抗病毒预防。
研究设计与样本
- ASCO与IDSA召集更新专家组,对2011年5月至2016年11月的相关研究进行系统综述,推荐基于专家组对证据的审查。
主要发现
- 更新版系统综述新增6项新的或更新的荟萃分析和6项新的原始研究。
关键数值与推荐
- 预计出现深度、迁延性中性粒细胞减少(<100个中性粒细胞/µL持续>7天)或其他高危因素的患者推荐抗菌和抗真菌预防。
- 单纯疱疹病毒血清阳性患者接受异基因造血干细胞移植或白血病诱导治疗时,应接受核苷类似物抗病毒预防(如阿昔洛韦)。
- 化疗方案相关肺孢子菌肺炎风险>3.5%者推荐肺孢子菌预防(如泼尼松等效剂量≥20 mg/日持续≥1个月或基于嘌呤类似物使用)。
- 乙型肝炎病毒再激活高风险患者推荐核苷酸逆转录酶抑制剂治疗(如恩替卡韦或替诺福韦)。
- 更新版指南还提供疫苗接种和避免长时间接触高浓度空气传播真菌孢子环境的推荐。
临床怎么用
- 对预计出现深度、迁延性中性粒细胞减少(<100个中性粒细胞/µL持续>7天)或其他高危因素的患者推荐抗菌和抗真菌预防。
- 单纯疱疹病毒血清阳性患者接受异基因造血干细胞移植或白血病诱导治疗时,应接受核苷类似物抗病毒预防(如阿昔洛韦)。
- 化疗方案相关肺孢子菌肺炎风险>3.5%者推荐肺孢子菌预防(如泼尼松等效剂量≥20 mg/日持续≥1个月或基于嘌呤类似物使用)。
- 乙型肝炎病毒再激活高风险患者推荐核苷酸逆转录酶抑制剂治疗(如恩替卡韦或替诺福韦)。
- 更新版指南还提供疫苗接种和避免长时间接触高浓度空气传播真菌孢子环境的推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. METHODS: ASCO and IDSA convened an update Expert Panel and conducted a systematic review of relevant studies from May 2011 to November 2016. The guideline recommendations were based on the review of evidence by the Expert Panel. RESULTS: Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. RECOMMENDATIONS: Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other risk factors. Herpes simplex virus-seropositive patients undergoing allogeneic hematopoietic stem-cell transplantation or leukemia induction therapy should receive nucleoside analog-based antiviral prophylaxis, such as acyclovir. Pneumocystis jirovecii prophylaxis is recommended for patients receiving chemotherapy regimens that are associated with a > 3.5% risk for pneumonia as a result of this organism (eg, those with ≥ 20 mg prednisone equivalents daily for ≥ 1 month or on the basis of purine analog usage). Treatment with a nucleoside reverse transcription inhibitor (eg, entecavir or tenofovir) is recommended for patients at high risk of hepatitis B virus reactivation. Recommendations for vaccination and avoidance of prolonged contact with environments that have high concentrations of airborne fungal spores are also provided within the updated guideline. Additional information is available at www.asco.org/supportive-care-guidelines .
引用
- Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 30179565. doi:10.1200/JCO.18.00374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。